ANEMOCYTE is attending the ISCTAsia 2026 conference in Singapore.

Anemocyte is a leading Italian Biotech Manufacturing Organization (BMO) specializing in innovation, development, manufacturing, and analytical services for the Cell & Gene Therapy (CGT) and Nucleic Acids ecosystem. We bridge the gap between scientific innovation and clinical reality through cutting-edge platforms: 🔹 pDNA Platform: Expert manufacturing of Plasmid DNA (R&D, High-Quality, and GMP) for Viral Vectors and mRNA applications. We offer customized solutions and Off-the-Shelf pDNA products (including specialized LVV platforms) to streamline your supply chain and accelerate speed-to-clinic. 🔹 mRNA & AMCAP™ Technology: mRNA manufacturing for vaccines and therapeutic treatments. Our proprietary AMCAP™ (patent-pending) "One-Pot" synthesis technology delivers high-yield, superior Cap-1 mRNA with reduced complexity and costs. 🔹 AMClarity: Our specialized division for Visual Inspection Confidence. We provide precision-mimicking defective reference standards (defect kit) and GMP qualification services to ensure the highest quality for high-stakes life science products. Our Experience: • 25+ years of experience in the development and manufacturing (from R&D to GMP) of Cell and Gene Therapies and Nucleic Acids. • A client-centric approach: from custom projects to ready-to-use Off-the-shelf mRNA/pDNA and AMCAP™ IVT Kits, we provide the flexibility needed to scale your innovation. Empowering the future of medicine through biotech manufacturing innovation.

Founded 2017